Videos

Watch our experts break down complex topics and suggest ways to adjust your business. Gain clarity, step-by-step.

Mitchell Finkel

RSV Prevention, Part I: Pediatric Monoclonal Antibodies

Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.

NCDs, Part III: Agency Mandates, Decisions, Coverage and Access

Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.

Medicare Advantage, Part II: Influencing CMS Policy

Tune into the second episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Center for Medicaid and Medicare (CMS) employees Sean Creighton and Tom Kornfield discuss their thoughts on the best ways for health plans to influence CMS decision making, including timing of engagement and critical messaging elements.

Sean Creighton

Medicare Advantage, Part I: The Future of MA

Tune into the first episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Centers for Medicare & Medicaid Services (CMS) employees, Sean Creighton and Tom Kornfield, discuss the outlook for Medicare Advantage, factors that will influence growth of the program, and a behind-the-scenes look at CMS policymaking considerations.

Shelby Harrington

NCDs, Part II: Evidence Development to Fulfill CED Requirements

Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.

Mark von Eisenburg

NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers

Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.

HIV/AIDS Prevention and Treatment, Part II

Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome leaders from the National Alliance of State & Territorial AIDS Directors (NASTAD) to discuss how HIV state policies have changed in light of advancements in prevention and treatment, and the key to ending the HIV and viral hepatitis epidemics in the US.

World AIDS Day: HIV/AIDS Prevention and Treatment

Tune into another episode of Avalere Health Essential Voice. In this segment, we welcome Carl Schmid, Executive Director at the HIV + Hepatitis Policy Institute, to discuss how HIV prevention and treatment policy influence broader health policy issues as we commemorate World AIDS Day on December 1.

Medicare Part D, Part V: What’s Next for CMMI?

Tune into the fifth and final episode of the Avalere Health Essential Voice miniseries focused on Medicare Part D. In this segment, our experts discuss the Center for Medicare & Medicaid Innovation (CMMI) and its strategic direction for the coming year, particularly as it relates to the Part D program.

Amelia Nell

Cell and Gene Therapy in Oncology, Part III

Tune into another episode of the Avalere Health Essential Voice podcast series focused on disease education. In this segment, the final in our series on cell and gene therapies, experts from our Market Access practice discuss the need for patient support in cell and gene therapies, and the role that manufacturers and other stakeholders can play in providing it.

The Coverage Gap and Medicaid Expansion

Tune into another episode of Avalere Health Essential Voice. In this segment, our experts discuss the forthcoming debate around the coverage gap in non-Medicaid expansion states, potential policy options, and the impact on key stakeholders.

Sign up to receive more insights about Vaccines and Public Health
Please enter your email address to be notified when new Vaccines and Public Health insights are published.

Back To Top